Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that Botox injections may increase hair count and reduce hair loss in men with androgenetic alopecia, potentially through increased blood flow and oxygen to the scalp.

This review reports favorable outcomes for botulinum toxin injections in androgenic alopecia treatment, but findings are limited by small sample sizes and lack of control groups.

This study found that combining botulinum toxin A injections with finasteride and minoxidil increased hair density in patients with androgenic alopecia more effectively than finasteride and minoxidil alone.

This study found that botulinum toxin type A injections in stressed mice appeared to normalize hair follicle regeneration cycles and reduced stress-related hair loss indicators.

This study found that vibration anesthesia significantly reduced pain during botulinum toxin injections for masseter reduction without affecting the injection's diffusion or causing adverse effects, and high patient satisfaction was also reported.

This meta-analysis and systematic review found that botulinum toxin injections significantly increased hair count in patients with androgenetic alopecia compared to controls, indicating promising efficacy and good safety.

In this case study, Botulinum toxin type A injections were associated with improved hair growth and scalp condition in a patient with radiation-induced alopecia, though the mechanisms remain speculative.

In this case report, botulinum neurotoxin injections were associated with a 6-month cessation of priapism episodes in a young man with recurring low-flow priapism, following unsuccessful conventional treatments.

In this study, BTXA injections did not effectively treat recalcitrant alopecia areata or improve hair regrowth in most patients, suggesting its limitations as an alternative therapy.

In this study, researchers found that type A botulinum toxin injections can reduce hypertrophic scars effectively, though more high-quality studies are needed to confirm the precision and stability of these therapeutic effects.

In this case study, repetitive botulinum type A toxin injections led to almost complete resolution of severe chronic pain in a patient with Parry-Romberg syndrome.

This study found that for treating androgenetic alopecia, LC hair essence serum injections provided excellent results with fewer side effects compared to botulinum toxin A, which also showed significant efficacy but with higher associated costs and more frequent side effects.

Botulinum A toxin injections reduced pain and promoted hair regrowth in a woman with a rare form of alopecia areata.

This study concluded that intradermal botulinum toxin type A injections are the preferred treatment for Frey's syndrome, with significant improvements in functional quality of life reported by patients.

This registered trial will investigate whether preoperative botulinum toxin can improve hair transplantation outcomes by enhancing blood flow and reducing ischemia in the scalp.

This study found that one session of intradermal botulinum toxin type A injection decreased scalp sebum secretion and perception of greasiness more effectively than saline for up to 3 months.

In this study, botulinum toxin type A injections reduced the severity of treatment-resistant scalp psoriasis in more patients compared to placebo over a 12-week period.

This case report describes a 27-year-old woman who developed an epidermoid cyst in the left parotid gland following botulinum toxin injections, which was successfully treated with surgical removal.

In this randomized controlled trial, both Botulinum Toxin-A and Triamcinolone Acetonide showed substantial effectiveness in treating patchy Alopecia Areata, but Botulinum Toxin-A avoided complications while Triamcinolone led to skin atrophy in 16.7% of patients.

This case report describes a 29-year-old woman with Female Pattern Hair Loss whose hair thinning reduced one month after botulinum toxin treatment.

In this study, complete recovery from folliculitis dissecans was observed after intradermal botulinum toxin A injections, with the effect attributed to the host response rather than direct bacterial action.

This study outlines a randomized trial investigating the effects of botulinum toxin administered before hair transplantation to potentially improve outcomes by enhancing blood flow and reducing graft failure due to ischemia in androgenetic alopecia patients.

In this review, experts discuss the low but significant risk of serious eye complications from popular minimally invasive cosmetic procedures like fillers and botulinum toxin injections, underscoring the need for awareness, careful patient selection, and adherence to safe practices to help prevent these outcomes.

This article reviews the literature on the off-label use of botulinum toxin for dermatological conditions, highlighting its potential effectiveness in treating rosacea, anal fissures, Raynaud phenomenon, hypertrophic scars, keloids, and hidradenitis suppurativa.

This case report describes a 34-year-old Asian female who experienced prolonged localized facial blanching following botulinum toxin type A injection, marking the first such documented case in this population.

In this narrative review, the authors explored various rehabilitative techniques, including injections and physical therapies, that may enhance aesthetics and psychosocial wellbeing in patients with disabilities, emphasizing a multidisciplinary approach to improve both functional and cosmetic outcomes.

This study found that subcutaneous administration of Botulinum toxin type A significantly reduced histamine-induced itch intensity and neurogenic inflammation in human skin compared to saline.

In this study on rats, botulinum toxin–A injection was reported to reduce contraction in wounds and skin grafts, with changes in inflammation and collagen arrangement also observed.

This study reports the effective use of botulinum toxin A in treating multiple facial apocrine hidrocystomas in a 29-year-old man, a case not previously documented in English-language literature.

In this randomized, controlled, clinical trial, the researchers found that injectable botulinum toxin did not promote hair growth in men with androgenetic alopecia over 12 or 24 weeks, showing no benefit in improving hair density compared to placebo.